European Society of Cardiology
Skip navigation links
About the ESC
Guidelines & Surveys
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe

The ACCA Clinical Decision-Making Toolkit 

Acute Cardiac Care 2013

Topics: Acute Coronary Syndromes (ACS)
Date: 12 Oct 2013
A key instrument for quality improvement and clinical training

Discover more on the ACCA decision-making toolkit

Practitioners managing patients with acute cardiovascular diseases continue to face difficulties in bedside clinical decision-making for these patients. Despite major advances in the field, we are still confronted with clinical and logistical difficulties in the management of high risk patients with important variations in the quality of care among different centres, regions and countries. Also significant post-discharge mortality in patients with acute coronary syndromes and other acute cardiovascular syndromes persists.  In alignment with its mission to improve the quality of care and outcomes of patients with acute cardiovascular diseases, ACCA is developing a Clinical Decision-Making Toolkit which will be a key instrument to help practitioners make the best bedside clinical decisions, when managing patients with acute cardiovascular diseases.

Challenging unmet needs in acute cardiac care- A set of tools The Decision-Making Toolkit will be a multidimensional set of instruments available through different platforms (application for smartphones/tablets, web-based documents, printed materials…).

Toolkit: abridged version: Algorithms in main CV syndromes
Aimed to facilitate implementation of ESC guidelines; this "easy to use" booklet is authored by many European Expert & Key Opinion Leaders in the field of acute cardiovascular care.

Get your Acute Cardiovascular Care Clinical Decision-Making Toolkit by visiting the ESC / ACCA stand number A1 or discover and download the abridged version.

The Clinical Decision-Making Toolkit is supported by unrestricted educational grants from AstraZeneca and Novartis.